Nov 21,2019 : ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that as part of an exclusive licensing agreement between GSK and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the company develop an nvestigational broadly neutralising antibody (bNAb) N6LS for the treatment and prevention of HIV-1.
These antibodies can recognise and block the entry of different strains of HIV into healthy cells.
is an antiviral bNAb that works by binding to a specific site (gp120) on the surface of HIV that prevents its entry into uninfected immune system cells (CD4+ T-cells).
By blocking HIV’s entry into human CD4+ cells, HIV replication stops, and the HIV transmission procedure may be prevented. https://viivhealthcare.com/en-gb/media/press-releases/2019/november/viiv-healthcare-announces-exclusive-licensing-agreement-with-the/